

## PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: Mail

Mail Stop ISSUE FEE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
or Fax (571) 273-2885

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee communications.

CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)

23347 7590 08/25/2005

GLAXOSMITHKLINE  
CORPORATE INTELLECTUAL PROPERTY, MAI B475  
FIVE MOORE DR., PO BOX 13398  
RESEARCH TRIANGLE PARK, NC 27709-3398  
11/15/2005 TBESHAH2 00000064 071392 09914830

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

## Certificate of Mailing or Transmission

I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO (571) 273-2885, on the date indicated below.

Marjorie J. Pfeiffer

(Depositor's name)

Marjorie J. Pfeiffer

(Signature)

November 14, 2005

(Date)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/914,830	09/24/2001	Anthony Patrick Jones	PG3614USW	4156

TITLE OF INVENTION: MEDICAMENT DELIVERY SYSTEM

APPLN. TYPE	SMALL ENTITY	ISSUE FEE	PUBLICATION FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	NO	\$1400	\$0	\$1400	11/25/2005
EXAMINER	ART UNIT	CLASS-SUBCLASS			
MITCHELL, TEENA KAY	3743	128-200230			

1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363).

- ☐ Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached.  
☐ "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer Number is required.

2. For printing on the patent front page, list

- (1) the names of up to 3 registered patent attorneys or agents OR, alternatively,  
(2) the name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed.

1. James F. Riek

2.

3.

3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)

PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment.

(A) NAME OF ASSIGNEE

SMITHKLINE BEECHAM CORPORATION

(B) RESIDENCE: (CITY and STATE OR COUNTRY)

Philadelphia, Pennsylvania

Please check the appropriate assignee category or categories (will not be printed on the patent): ☐ Individual ☒ Corporation or other private group entity ☐ Government

4a. The following fee(s) are enclosed:

- ☒ Issue Fee  
☐ Publication Fee (No small entity discount permitted)  
☒ Advance Order - # of Copies 4

4b. Payment of Fee(s):

- ☐ A check in the amount of the fee(s) is enclosed.  
☐ Payment by credit card, Form PTO-2038, is attached.  
☒ The Director is hereby authorized by charge the required fee(s), or credit any overpayment, to Deposit Account Number 07-1392 (enclose an extra copy of this form).

5. Change in Entity Status (from status indicated above)

- ☐ a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27. ☐ b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2).

The Director of the USPTO is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above. NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant, a registered attorney or agent, or the assignee or other party in interest as shown by the records of the United States Patent and Trademark Office.

Authorized Signature

James P. Riek

Date

11-11-2005

Typed or printed name


Registration No.

39,009

This collection of information is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

BEST AVAILABLE COPY



NOV 14 2005 4:30PM

GLAXO WELLCOME

NO. 8493 P. 1



GlaxoSmithKline

To BOX ISSUE FEE

Company USPTO

Fax (571) 273-2885

From Marjorie J. Pfeiffer

Tel 1-919-483-9038; Facsimile: 1-919-483-7988

E-mail [marjorie.j.pfeiffer@gsk.com](mailto:marjorie.j.pfeiffer@gsk.com)

Date November 14, 2005 Pages including cover 4

Subject Fee(s) Transmittal - Appl. No. 09/914,830

GlaxoSmithKline  
PO Box 13398  
Five Moore Drive  
Research Triangle Park  
North Carolina 27709

Tel: 919 483 2100  
[www.gsk.com](http://www.gsk.com)

Re: Fee(s) Transmittal  
Application of Anthony Patrick JONES et al.  
U.S. Serial No.: 09/914,830; Filed: September 24, 2001  
Date of Mailing "Notice of Allowance and Fees Due": August 25, 2005  
Confirmation No. 4156  
Title: *Medicament Delivery System*  
Attorney Docket No. PU3614USw

Attached:

1. Fee(s) Transmittal (Part B), in duplicate  
with Certificate of Transmission (37 CFR 1.8(a))

RESEND

*This supersedes fee(s)  
transmittal at 2:26pm  
on 11/14/05 with unsigned  
Certificate of Transmission.*

The information contained in these documents is confidential and may also be privileged and is intended for the exclusive use of the addressee designated above. If you are not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, any disclosure, reproduction, distribution, or any other dissemination or use of this communication is strictly prohibited. If you have received this transmission in error please contact us immediately by telephone so that we can arrange for its return.



## Auto-Reply Facsimile Transmission

TO:

Fax Sender at 919 483 7988

Fax Information

Date Received:

Total Pages:


11/14/2005 2:23:53 PM [Eastern Standard Time]

3 (including cover page)

**ADVISORY:** This is an automatically generated return receipt confirmation of the facsimile transmission received by the Office. Please check to make sure that the number of pages listed as received in Total Pages above matches what was intended to be sent. Applicants are advised to retain this receipt in the unlikely event that proof of this facsimile transmission is necessary. Applicants are also advised to use the certificate of facsimile transmission procedures set forth in 37 CFR 1.8(a) and (b), 37 CFR 1.6(f). Trademark Applicants, also see the Trademark Manual of Examining Procedure (TMEP) section 306 et seq.

Received  
Cover  
Page

=====>

NOV 14 2005 4:18PM	GLAXO WELLCOME	NO. 8493 P. 1
<b>FAX</b>		 GlaxoSmithKline
To	BOX ISSUE PCE	GlaxoSmithKline PO Box 12210 Five Mounds Drive Research Triangle Park North Carolina 27709
Company	USPTO	Tel: 919 483 2100 www.gsk.com
Fax	(571) 273-2885	
From	Marjorie J. Proffler	
Tel	1-919-483-9089; Facsimile: 1-919-483-7988	
E-mail	marjorie.j.proffler@uspto.gov	
Date	November 14, 2005	Pages including cover 3
Subject	Fee(s) Transmittal - Appl. No. 06/214,830	
Re:	Fee(s) Transmittal Application of Anthony Patrick JONES et al U.S. Patent No.: 06/214,830; Filed: September 24, 2001 Date of Mailing "Notice of Allowance and Fee Due": August 26, 2005 Confirmation No. 6156 Title Medicament Delivery System Attorney Docket No. PU3614USW	
Attached:	1. Fee(s) Transmittal (Part B), in duplicate with Certificate of Transmission (37 CFR 1.8(a))	
<small>The information contained in these documents is confidential and may also be privileged and is intended for the exclusive use of the addressee design and above. If you are not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, any disclosure, reproduction, distribution, or any other dissemination or use of this communication is strictly prohibited. If you have received this transmission in error please contact us immediately by telephone so that we can arrange for its return.</small>		
PAGE 10 * RCVD AT 11/14/2005 2:23:53 PM [Eastern Standard Time] * SVR:USPTO-EFXRF-6/28 * DNIS:2732885 * CSID:919 483 7988 * DURATION (mm:ss):01:42		

**BEST AVAILABLE COPY**